Could Structure Therapeutics Become the Next Novo Nordisk?

Structure Therapeutics (GPCR 0.84%) and Novo Nordisk (NVO -0.68%) have one big thing in common: the desire to compete in the bustling market for obesity therapies. While the pre-revenue biotech is still a fledgling in the midst of its attempt to develop its first approved medicine, some recently released data suggests that Novo Nordisk might want to keep an eye out. This market won't be winner-take-all That's a tall order, as Novo's trailing-12-month revenue is $35.5 billion, and the cardiometabolic segment ...